Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer
Abstract A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS). Of the 40 evaluable female patients, the ORR was 62.5%. All patients have responded with one (2.5%) complete response, 24 (60%) partial response, 12 (30%) stable disease, and 3 (7.5%) progressive disease. The OS and PFS were 20 months (95% CI: 11.9–28 months) and 13 months (95% CI: 8.0–17.9 months), respectively. Survival (OS and PFS) were longer in patients with good performance status and in patients older than 65 years (P < 0.05). The most frequently observed toxicities were rash/dry skin (80%), diarrhea (42.5%), and vomiting/anorexia (32.5%). Four patients developed grade 3 toxicities (rash and diarrhea) but did not require either dose reduction or discontinuation. Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Medical oncology - 29(2011), 2 vom: 12. März, Seite 595-599 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Jing [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC 2011 |
|---|
| doi: |
10.1007/s12032-011-9891-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2055157639 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2055157639 | ||
| 003 | DE-627 | ||
| 005 | 20230516093907.0 | ||
| 007 | tu | ||
| 008 | 200819s2011 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12032-011-9891-2 |2 doi | |
| 035 | |a (DE-627)OLC2055157639 | ||
| 035 | |a (DE-He213)s12032-011-9891-2-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Deng, Jing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC 2011 | ||
| 520 | |a Abstract A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS). Of the 40 evaluable female patients, the ORR was 62.5%. All patients have responded with one (2.5%) complete response, 24 (60%) partial response, 12 (30%) stable disease, and 3 (7.5%) progressive disease. The OS and PFS were 20 months (95% CI: 11.9–28 months) and 13 months (95% CI: 8.0–17.9 months), respectively. Survival (OS and PFS) were longer in patients with good performance status and in patients older than 65 years (P < 0.05). The most frequently observed toxicities were rash/dry skin (80%), diarrhea (42.5%), and vomiting/anorexia (32.5%). Four patients developed grade 3 toxicities (rash and diarrhea) but did not require either dose reduction or discontinuation. Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC. | ||
| 650 | 4 | |a Gefitinib | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Pretreated | |
| 650 | 4 | |a Non-small-cell lung cancer | |
| 700 | 1 | |a Fang, Wei Jia |4 aut | |
| 700 | 1 | |a Zhang, Xiao Chen |4 aut | |
| 700 | 1 | |a Wu, Dong Ping |4 aut | |
| 700 | 1 | |a Fang, Hong Ming |4 aut | |
| 700 | 1 | |a Chen, Jing |4 aut | |
| 700 | 1 | |a Qian, Jiong |4 aut | |
| 700 | 1 | |a Mou, Hai Bo |4 aut | |
| 700 | 1 | |a Chu, Bin Bin |4 aut | |
| 700 | 1 | |a Xu, Nong |4 aut | |
| 700 | 1 | |a Teng, Li Song |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical oncology |d Springer US, 1994 |g 29(2011), 2 vom: 12. März, Seite 595-599 |w (DE-627)182362183 |w (DE-600)1201189-7 |w (DE-576)049952552 |x 1357-0560 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2011 |g number:2 |g day:12 |g month:03 |g pages:595-599 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12032-011-9891-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2011 |e 2 |b 12 |c 03 |h 595-599 | ||